AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31304993 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week
Number of subjects: 217
Study 31304993 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 217
Study 27147222 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Number of subjects: 15
Study 26747224 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-100
Number of subjects: 224
Study 26747224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 26747224 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-100 (pylorus ring-preserving PD subgroup)
Number of subjects: 224
Study 26747224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pylorus ring-preserving PD subgroup)
Number of subjects: 224
Study 24351233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450-600 mg/d
Number of subjects: 0
Study 24351233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150-300 mg/d
Number of subjects: 0
Study 24351233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 3-4 mg/d
Number of subjects: 0
Study 24351233 — intervention group
Group type: COMPARATOR
Intervention: All treatments (Pregabalin and Lorazepam)
Number of subjects: 0
Study 22664339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eprinomectin (≥ 0.05 mg/kg) every 28 days for eight treatments during lactation
Number of subjects: 923
Study 22664339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 923
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction interventions with high self-regulation characteristics
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal reformulation
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of a patient's partner or relative
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect sizes for weight loss in the short term (<6 months)
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect sizes for weight loss in the longer term (>6 months)
Number of subjects: 34
Study 19687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect sizes for A1C outcomes
Number of subjects: 34
Study 17953497 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (instructions to form specific if-then plans)
Number of subjects: 0
Study 17953497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implementation intention)
Number of subjects: 0
Study 16135464 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (pemetrexed 500 mg/m2 followed by gemcitabine 1,250 mg/m2 on day 1 and gemcitabine on day 8)
Number of subjects: 152
Study 16135464 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule C (gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8)
Number of subjects: 152
Study 16135464 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 152
Study 16135464 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8)
Number of subjects: 152
Study 16135464 — intervention group
Group type: EXPERIMENTAL
Intervention: All schedules
Number of subjects: 152
Study 11930874 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10099065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol once daily
Number of subjects: 0
Study 10099065 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nifedipine retard twice daily
Number of subjects: 0
Study 7645711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinner fibrescope (3.7 mm diameter)
Number of subjects: 84
Study 7645711 — intervention group
Group type: COMPARATOR
Intervention: Thicker fibrescope (5.0 mm diameter)
Number of subjects: 84
Study 31034591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for Cancer Patients (EXCAP)
Number of subjects: 252
Study 31034591 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study 28164346 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmithoylethanolamide/polydatin 200 mg/20 mg
Number of subjects: 54
Study 28164346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26994230 — intervention group
Group type: EXPERIMENTAL
Intervention: extrafascial injection
Number of subjects: 40
Study 26994230 — intervention group
Group type: COMPARATOR
Intervention: conventional intrafascial injection
Number of subjects: 40
Study 24608069 — intervention group
Group type: COMPARATOR
Intervention: 400 mg film-coated tablet (fasted)
Number of subjects: 12
Study 24608069 — intervention group
Group type: EXPERIMENTAL
Intervention: four 100 mg EC tablets (fasted)
Number of subjects: 12
Study 24608069 — intervention group
Group type: EXPERIMENTAL
Intervention: one 400 mg GFS dose (fasted)
Number of subjects: 12
Study 24608069 — intervention group
Group type: EXPERIMENTAL
Intervention: four 100 mg EC tablets (after a high-fat meal)
Number of subjects: 12
Study 22568162 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT/VCUG combination group
Number of subjects: 22
Study 22568162 — intervention group
Group type: COMPARATOR
Intervention: VCUG-single group
Number of subjects: 22
Study 18851861 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 123
Study 18851861 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 17177199 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose 182 mg/day)
Number of subjects: 58
Study 17177199 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 58
Study 17177199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 14667422 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping group treatment (n=4)
Number of subjects: 19
Study 14667422 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mapping group treatment (n=4)
Number of subjects: 19
Study 14667422 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=5 in Experiment 1; n=10 in Experiment 2)
Number of subjects: 19
Study 14667422 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping group treatment (n=9 in Experiment 2)
Number of subjects: 19
Study 11724078 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with high-fat food
Number of subjects: 16
Study 11724078 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with orange juice
Number of subjects: 16
Study 11724078 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with food
Number of subjects: 16
Study 11724078 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with antacids
Number of subjects: 16
Study 9190323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (up to 600mg daily, mean daily dose 250 to 290mg)
Number of subjects: 35
Study 9190323 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (up to 100mg daily, mean daily dose 59.1 to 63.6mg) with or without levomepromazine (100mg)
Number of subjects: 35
Study 7955956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG; 500 mg daily plus hydrocortisone 40 mg daily)
Number of subjects: 293
Study 7955956 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone (MPA; 1,000 mg daily per os)
Number of subjects: 293
Study 7955956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after Medroxyprogesterone (MPA)
Number of subjects: 293
Study 7955956 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA) after Aminoglutethimide (AG)
Number of subjects: 293
Study 3673915 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 406
Study 3673915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 29497150 — intervention group
Group type: COMPARATOR
Intervention: IND (indapamide 1.25-2.5 mg daily)
Number of subjects: 100
Study 29497150 — intervention group
Group type: EXPERIMENTAL
Intervention: IND/KCl (indapamide 1.25-2.5 mg daily plus potassium chloride 40 mmol daily)
Number of subjects: 100
Study 29497150 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in UA between IND/KCl and IND groups
Number of subjects: 100
Study 25727443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hydrated collagenated cortico-cancellous porcine bone (coll group)
Number of subjects: 28
Study 25727443 — intervention group
Group type: COMPARATOR
Intervention: Cortical porcine bone and a collagen membrane (cort group)
Number of subjects: 28
Study 25703419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 3291
Study 25703419 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3291
Study 23254962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy plus radiation therapy (IC + RT) with 2-3 cycles of cisplatin (80 mg/m²) and fluorouracil (500 mg/m²), followed by radiotherapy.
Number of subjects: 212
Study 23254962 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin (40 mg/m²) for 6-7 cycles during radiotherapy.
Number of subjects: 212
Study 23254962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) with similar chemotherapy regimen as IC + RT followed by CCRT regimen.
Number of subjects: 212
Study 23254962 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (RT).
Number of subjects: 212
Study 19854590 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg IV single dose)
Number of subjects: 0
Study 19854590 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 19162371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine only
Number of subjects: 164
Study 19162371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and a nail pick
Number of subjects: 164
Study 19162371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and a nail brush
Number of subjects: 164
Study 15844838 — intervention group
Group type: EXPERIMENTAL
Intervention: YMJ derivatives (YMJd)
Number of subjects: 35
Study 15844838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14597500 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially desirable information (occupation, socioeconomic status, relationship with primary care physician) included
Number of subjects: 2872
Study 14597500 — intervention group
Group type: COMPARATOR
Intervention: Patient race/ethnicity (African Americans, Hispanics, and whites)
Number of subjects: 2872
Study 10579275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced enteral nutrition (started at a feeding rate that met estimated energy and nitrogen requirements)
Number of subjects: 82
Study 10579275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced enteral nutrition
Number of subjects: 82
Study 10579275 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (gradually increased from 15 mL/hr up to estimated energy and nitrogen requirements)
Number of subjects: 82
Study 8568045 — intervention group
Group type: EXPERIMENTAL
Intervention: IDT of the 753-Hz component
Number of subjects: 10
Study 8568045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of the IDTs of the two components
Number of subjects: 10
Study 8568045 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between the two IDTs
Number of subjects: 10
Study 8568045 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly selected IDT of one of three components (553, 753, or 953 Hz)
Number of subjects: 10
Study 1744924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of leucovorin
Number of subjects: 5
Study 1744924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of leucovorin
Number of subjects: 5
Study 6126069 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-oriented group therapy
Number of subjects: 80
Study 6126069 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics and social skills training
Number of subjects: 80
Study 31504572 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA-eDS tool (electronic decision support)
Number of subjects: 176
Study 29144630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal onlay graft placement
Number of subjects: 136
Study 29144630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorso-lateral onlay graft placement
Number of subjects: 136
Study 29144630 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 136
Study 26259617 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 264
Study 26259617 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 264
Study 26259617 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 264
Study 25261272 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 0
Study 25261272 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 0
Study 21705294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 12 weeks
Number of subjects: 36
Study 21705294 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 36
Study 20074897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg/kg hydroxyzine (G1)
Number of subjects: 100
Study 20074897 — intervention group
Group type: COMPARATOR
Intervention: Water 0.1 ml/kg (G2)
Number of subjects: 100
Study 17409263 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplements (G) - 6.13 +/‐ 0.09% glucose
Number of subjects: 15
Study 17409263 — intervention group
Group type: COMPARATOR
Intervention: Artificial sweeteners (NG)
Number of subjects: 15
Study 14986145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort TE (UTE) pulse sequences
Number of subjects: 19
Study 14986145 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhancement administered in 11 cases
Number of subjects: 19
Study 11566640 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplement (15 g psyllium/d)
Number of subjects: 68
Study 11566640 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 9624696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses from Groups I and II
Number of subjects: 10
Study 9624696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses from Group IV
Number of subjects: 10
Study 9624696 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens cytology (CLC)
Number of subjects: 10
Study 9624696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tests for lens movement, lens comfort, tear break-up time, and fluorescein staining
Number of subjects: 10
Study 7868693 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary)
Number of subjects: 363
Study 7868693 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration (performed under general anaesthesia)
Number of subjects: 363
Study 7868693 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 363
Study 7868693 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 363
Study 2829625 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 10
Study 2829625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29956790 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (20 g)
Number of subjects: 5
Study 29956790 — intervention group
Group type: COMPARATOR
Intervention: Control (sucrose)
Number of subjects: 5
Study 26754305 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine soft capsules (600 μg)
Number of subjects: 70
Study 26754305 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine tablets (200 μg)
Number of subjects: 70
Study 26754305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low, medium, and high strengths of levothyroxine soft capsules
Number of subjects: 70
Study 24828094 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 100
Study 24828094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23174063 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-90 plate fixation
Number of subjects: 10
Study 23174063 — intervention group
Group type: COMPARATOR
Intervention: Parallel plate fixation
Number of subjects: 10
Study 20631675 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) treatment
Number of subjects: 0
Study 20631675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18614402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg slow release indapamide, with the option of 2‐4 mg perindopril
Number of subjects: 3336
Study 18614402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3336
Study 16060427 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise activity
Number of subjects: 12
Study 16060427 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (control) activity
Number of subjects: 12
Study 16060427 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual occlusion conditions
Number of subjects: 12
Study 12614526 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 66
Study 12614526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 66
Study 12614526 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 66
Study 10651119 — intervention group
Group type: EXPERIMENTAL
Intervention: CD(34+)-enriched peripheral blood stem cells (PBSC)
Number of subjects: 7
Study 10651119 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated PBSC
Number of subjects: 7
Study 8966389 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH stimulation test (0.25 mg iv bolus)
Number of subjects: 13
Study 8966389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral midnight DEX inhibition test
Number of subjects: 13
Study 8966389 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g 2-h oral glucose tolerance test (OGTT)
Number of subjects: 13
Study 8966389 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio
Number of subjects: 13
Study 1995211 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training at ventilatory threshold intensity for three months
Number of subjects: 14
Study 1995211 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training for three months
Number of subjects: 14
Study 1995211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 14
Study 6125820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bag-changing regimen
Number of subjects: 12
Study 6125820 — intervention group
Group type: COMPARATOR
Intervention: Weekly bag-changing regimen
Number of subjects: 12
Study 6125820 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex Foley catheters
Number of subjects: 12
Study 6125820 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic catheters
Number of subjects: 12
Study 6125820 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial treatment
Number of subjects: 12
Study 6125820 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodes of pyrexia
Number of subjects: 12
Study 31578564 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO-HD
Number of subjects: 40
Study 31469393 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy only
Number of subjects: 438
Study 31469393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential choice (colonoscopy and then FIT)
Number of subjects: 438
Study 31469393 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice (colonoscopy or FIT)
Number of subjects: 438
Study 26273677 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and rosiglitazone 4 mg/day (n = 30)
Number of subjects: 61
Study 26273677 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (n = 31)
Number of subjects: 61
Study 25251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 798
Study 25251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 798
Study 25251616 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 798
Study 22534708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (4 times/week, 45‐60 min/session)
Number of subjects: 54
Study 22534708 — intervention group
Group type: COMPARATOR
Intervention: Control group (orally instructed to increase physical activity)
Number of subjects: 54
Study 19502256 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan-eluting stents
Number of subjects: 45
Study 19502256 — intervention group
Group type: COMPARATOR
Intervention: Rapamycin-eluting stents
Number of subjects: 45
Study 19502256 — intervention group
Group type: COMPARATOR
Intervention: Rapamycin-eluting stents with adjunct oral valsartan
Number of subjects: 45
Study 17991651 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (1200 IU/d for 2 y)
Number of subjects: 90
Study 17991651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15852444 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg b.i.d.
Number of subjects: 656
Study 15852444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 11961446 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intravenous antibiotics (7 days for joint infection, 10 days for bone infection)
Number of subjects: 33
Study 11961446 — intervention group
Group type: COMPARATOR
Intervention: Long-term intravenous antibiotics (14 days for joint infection, 21 days for bone infection)
Number of subjects: 33
Study 9817288 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40
Study 9817288 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40